Cardiovascular disease: Should statin therapy be expanded in patients with CKD?

Nature Reviews Nephrology

Volumn 8, Issue 8, 2012, Pages 440-441

  Jablonski, Kristen L ^a   Chonchol, Michel ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DRUG EFFECT; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SUDDEN DEATH; SURVIVAL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS AS TOPIC; PRIMARY PREVENTION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84864334661     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.142     Document Type: Article

References (10)

1. Cholesterol Treatment Trialists Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists (CTT) Collaboration. Am. J. Cardiol. 75, 1130-1134 (1995).
2. Cholesterol Treatment Trialists Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet http://dx.doi.org/10.1016/S0140-6736(12)60367-5.
3. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004816 (2011). http://dx.doi.org/10.1002/14651858.CD004816.pub4.
4. Ray, K. K. et al. Statins and all-cause mortality in high-risk primary prevention: A meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170, 1024-1031 (2010).
5. Tonelli, M. et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis. CMAJ 183, E1189-E1202 (2011).
6. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).
7. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005). (Pubitemid 41058323)
8. Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
9. Navaneethan, S. D., Hegbrant, J. & Strippoli, G. F. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 20, 146-152 (2011).
10. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).